Records containing: HER2-positive Breast Cancer
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-02-12Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade
-
CLINICAL_TRIALS study record update · 2026-02-09Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer
-
CLINICAL_TRIALS study record update · 2026-02-09Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease
-
CLINICAL_TRIALS study record update · 2026-02-06Monitoring Early Response to Targeted Therapy in Stage IV Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer Patients With Advanced Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
-
CLINICAL_TRIALS study record update · 2026-01-28Tumor Microenvironment Alteration During Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer Patients
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-01-26A Phase 3, Randomized Advanced Breast Cancer Study Investigating RC48 Combined With Chemotherapy Versus Guideline-recommended Trastuzumab/Inetetamab Plus Chemotherapy in HER2-Positive Patients With Prior TOP1i-ADC Failure
-
CLINICAL_TRIALS study record update · 2026-01-22Efficacy and Safety of Trastuzumab-rezetecan in HER2-Positive and HER2-Low Breast Cancer: A Multicenter, Observational, Real-World Study Protocol
-
CLINICAL_TRIALS study record update · 2026-01-22A Randomized Controlled Phase Ill Clinical Study of BL-M07D1 for Injection Versus Trastuzumab Emtansine (T-DM1) in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
-
CLINICAL_TRIALS study record update · 2026-01-21Assessing REsponse to Neoadjuvant Taxotere and Trastuzumab in Nigerian Women With HER2-positive Breast Cancer (ARETTA)
-
CLINICAL_TRIALS study record update · 2026-01-15Contrast Enhanced Digital Mammography for Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy
-
CLINICAL_TRIALS study record update · 2026-01-12A Multi-center Prospective Observational Study to Assess the Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
-
CLINICAL_TRIALS study record update · 2026-01-06fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases
-
CLINICAL_TRIALS study record update · 2026-01-06Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy
-
CLINICAL_TRIALS study record update · 2025-12-31Phase 1 Trial of Tucatinib, Trastuzumab, and Capecitabine With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From HER-2 Positive Breast Cancer
-
CLINICAL_TRIALS study record update · 2025-12-15A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
-
CLINICAL_TRIALS study record update · 2025-12-04Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens: a Multicenter, International, Prospective, Non-interventional Study in Germany and Austria (TRACE)
-
CLINICAL_TRIALS study record update · 2025-11-26A Multicenter, Randomized, Open-label, Phase II Trial Aiming to Evaluate the Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2 Positive Breast Cancer Patients
-
CLINICAL_TRIALS study record update · 2025-11-26Basket Study for Oligo-metastatic Breast Cancer Part 1: Trastuzumab-deruxtecan for HER2-positive Oligo-metastatic Breast Cancer
-
CLINICAL_TRIALS study record update · 2025-11-20Phase 2, Multi-Center, Randomized, Open-Label Trial of BDC-1001 as a Single Agent and in Combination With Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab Deruxtecan
-
CLINICAL_TRIALS study record update · 2025-11-19A Phase 1a/1b Study of ELVN-002 Combined With Trastuzumab in Advanced Stage HER2+ Solid Tumors, and ELVN-002 Combined With Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast Cancer
-
CLINICAL_TRIALS study record update · 2025-11-19Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients
-
CLINICAL_TRIALS study record update · 2025-11-14An International, Multicenter, Open-label, Multicohort, Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases (the THERANOVA Study; NMN-02).
-
CLINICAL_TRIALS study record update · 2025-10-29Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy
-
CLINICAL_TRIALS study record update · 2025-10-22MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer
-
CLINICAL_TRIALS study record update · 2025-10-20A Phase III, Multicenter, Open-label, Randomized Study to Compare DB-1303 Versus T-DM1 in Patients With HER2-positive Unresectable/Metastatic Breast Cancer Who Have Been Treated With Trastuzumab and a Taxane (Dynasty-Breast01)